SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant volatility and community debate after pulling its compounded GLP-1 drug amid a patent infringement lawsuit from Novo Nordisk and increased regulatory scrutiny. Investors are sharply divided between calls for a short squeeze and a rebound from oversold levels, and predictions of further downside due to ongoing legal and business model challenges.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending due to its all-stock acquisition of Valaris (VAL), a strategic consolidation that the community largely views as enhancing its market leadership and pricing power in an anticipated offshore drilling upcycle, though some express concerns over share dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to a significant stock drop following its Q4 earnings report, which, despite showing profitability and prudent risk management, included a revenue miss and cautious guidance. The community is actively debating if the sell-off is an overreaction, viewing it as a potential buying opportunity given the company's strong fundamentals and AI-powered model, while others remain concerned about the broader fintech sector's volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is currently trending after its stock dramatically dropped following news of an SEC review into its accounting practices, reduced guidance, and the departure of its CFO and General Counsel. The community is sharply divided, with some calling it an extreme "overreaction" and a unique "buy-the-dip" opportunity, while others express severe concerns about potential financial improprieties, urging investors to "stay away" until more clarity emerges.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending after its Q4 earnings report, which, despite a revenue miss, beat EPS estimates and outlined an optimistic outlook for 2026, including the expiration of a value-destructive slab contract and ongoing POSCO partnership discussions. While some in the community view the stock's subsequent dip as a buying opportunity driven by these future catalysts, others remain deeply skeptical about its performance and management.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a sharp sell-off after issuing a weaker-than-expected revenue outlook and withdrawing its long-term targets, intensifying broader market fears about AI disruption to the traditional software sector. Despite beating Q4 earnings, the community is divided between those viewing the steep decline as an overreaction and a buying opportunity, and others who believe AI poses a fundamental threat to the SaaS business model.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as the community discusses its strategic acquisition of StereoLabs, which creates a unified lidar and camera platform for Physical AI applications. This move is largely seen as strengthening Ouster's market leadership and accelerating its path to profitability through StereoLabs' EBITDA-positive business.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as Morgan Stanley initiates coverage with an Overweight rating and a $37 price target, validating its strategic pivot to AI/HPC data centers amidst increasing hyperscaler capital expenditure. The community is actively discussing potential for a significant short squeeze and further contracts with major tech partners.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

REGENXBIO is trending due to intense community speculation surrounding an imminent FDA decision on its RGX-121 gene therapy for Hunter Syndrome, as a recent clinical hold on the program and a related therapy, stemming from a serious adverse event, has many anticipating a Complete Response Letter or a regulatory delay.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community discussion heats up around the recent inauguration of its Eagle Line, a significant step toward scalable solid-state battery production. While bulls anticipate potential OEM partnership announcements and licensing deals, others express frustration over the stock's performance and await concrete revenue details from the upcoming earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBX Biosciences (NASDAQ:MBX) Sees Strong Trading Volume - Here's What Happened

MBX Biosciences (NASDAQ:MBX) Sees Strong Trading Volume - What's Next...

Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MBX Biosciences, Inc. $MBX

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) in the third quarter, according to the company in its most...

MBX Biosciences, Inc. (NASDAQ:MBX) Short Interest Update

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 2,307,824 shares, a decline...

MBX Biosciences (NASDAQ:MBX) Now Covered by Analysts at Barclays

Barclays initiated coverage on MBX Biosciences in a research report on Tuesday. They set an "overweight" rating and a $66.00 target price on the stock...

MBX Biosciences (NASDAQ:MBX) Shares Down 6.8% - Here's What Happened

MBX Biosciences (NASDAQ:MBX) Trading Down 6.8% - Should You Sell...

MBX Biosciences (NASDAQ:MBX) Trading 7.6% Higher - Time to Buy?

MBX Biosciences (NASDAQ:MBX) Stock Price Up 7.6% - Time to Buy...

MBX Biosciences (NASDAQ:MBX) Trading Down 8.4% - Here's Why

MBX Biosciences (NASDAQ:MBX) Shares Down 8.4% - Time to Sell...

MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8% - Here's What Happened

MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8% - Should You Sell...

MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High - Still a Buy?

MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High - What's Next...

MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8% - Still a Buy?

MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8% - What's Next...

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

MBX
MBX Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MBX News

MBXMBX Biosciences Inc.